Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 9;10:18. doi: 10.1186/s40478-022-01321-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — Association between clinicopathological characteristics and percentage of S100B + cells at the whole tumour level in PitNETs. A Percentage of S100B + cells in PitNETs with a Ki67 index < 3% (n = 43, median = 0.40%) versus a Ki67 index ≥ 3% (n = 11, median = 0.02%), p = 0.01 (*). B Percentage of S100B + cells in non-invasive (n = 18, median = 0.09%) versus invasive PitNETs (n = 28, median = 0.39%). C Percentage of S100B + cells in gonadotroph tumours (n = 26, median = 0.20%), tumours of the Pit1 lineage (n = 20, median = 0.14%), and corticotroph tumours (n = 8, median = 0.73%). D Percentage of S100B + in gonadotroph tumours with a Ki67 index < 3% (n = 22, median = 0.47%) versus a Ki67 index ≥ 3% (n = 4, median = 0.02%), p = 0.007 (**). E Percentage of S100B + cells in gonadotroph tumours with a number of mitosis ≤ 2/10 HPFs (n = 22, median = 0.47%) versus a number of mitosis > 2/10 HPFs (n = 4, median = 0.02%), p = 0.03 (*). F Percentage of S100B + cells in non-proliferative (n = 23, median = 0.44%) versus proliferative gonadotroph tumours (n = 3, median = 0.02%), p = 0.01 (*). G Percentage of S100B + cells in non-invasive (n = 7, median = 0.22%) versus invasive gonadotroph tumours (n = 15, median = 0.19%). H Correlation analysis between the percentage of S100B + cells and the age of patients in gonadotroph tumours (n = 26). I Correlation analysis between the percentage of S100B + cells and the maximal diameter in gonadotroph tumours (n = 22). J Correlation analysis between the percentage of S100B + cells and the percentage of ERα + cells in gonadotroph tumours (n = 25). Graphs: median with interquartile range (A–G), scatter plot (H–J). Statistical tests: Mann–Whitney (A–G), Kruskall-Wallis (C), Spearman’s correlation (H–J). Abbreviations: human pituitary neuroendocrine tumours (PitNETs), high power fields (HPFs), non-significant (ns)